Recce Pharmaceuticals (ASX:RCE) progresses phase II clinical trial for skin infections

Recce Pharmaceuticals Limited (ASX:RCE) has successfully dosed 15 patients in its Phase II Acute Bacterial Skin and Skin Structure Infections (ABSSSI) clinical trial. The trial, which includes diabetic foot infections (DFI) and other wound infections, aims to assess the efficacy of RECCE® 327 topical gel (R327G) against ABSSSI. The company is on track to enroll 30 participants within this calendar year.

Executive Commentary on Phase II Clinical Trial Progress

We are thrilled to pass the halfway point of this pivotal Phase II clinical study for the unmet clinical need of topical skin infections. Indications of promising antibacterial effect is a significant achievement, with patient recruitment to be completed within the year. The market for ABSSSI is expanding as a result of an increase in the frequency of bacterial skin infections, particularly those brought on by drug-resistant strains. The acute lack of effective broad-spectrum antimicrobials contributes significantly to this challenge. Together with our initial data from the Therapeutic Goods Administrations (TGA) Special Access Scheme, which saw dramatic results in a number of DFI patients, we are excited to complete this trial and moreover, the potential of R327G to impact this growing global healthcare need.

Summary of Phase II Clinical Trial Progress

Recce Pharmaceuticals Limited (ASX:RCE) has made significant progress in its Phase II Acute Bacterial Skin and Skin Structure Infections (ABSSSI) clinical trial. The successful dosing of 15 patients and indications of promising antibacterial effect with RECCE® 327 topical gel (R327G) demonstrate the potential to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens. The company is expanding the clinical trial study locations across NSW and Victoria, broadening access to this novel treatment. With the global ABSSSI market size expected to reach USD $2.31 billion in the next 10 years, the potential impact of R327G on this growing global healthcare need is significant. Recce Pharmaceuticals aims to complete the trial and further develop the potential of R327G to address the unmet medical needs in treating skin infections.